
NextCell Pharma (Q4 2024/2025 update) - ProTrans-Young readout in Q3 2026

Redeye updates on NextCell following its Q4 report, which showed figures largely aligning with estimates. All patients in the ProTrans-Young trial are now dosed, setting up for a readout after summer 2026, which is the major catalyst ahead for the company.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[NextCell Pharma \(Q4 2024/2025 update\) - ProTrans-Young readout in Q3 2026](#)